Drug Details
| General Information of the Drug (ID: DR8995) | ||||
|---|---|---|---|---|
| Name |
Dapagliflozin
|
|||
| Synonyms |
Dapagliflozin; 461432-26-8; BMS-512148; Forxiga; Farxiga; BMS 512148; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; UNII-1ULL0QJ8UC; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-D-glucitol; 1ULL0QJ8UC; CHEMBL429910; CHEBI:85078; Dapagliflozin [USAN:INN]; BMS512148; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-ethoxybenzyl)phenyl)-6- (hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Forxiga (TN); CHEMBL3125458; (1S)-1,5-anhydro-1-[4-chloro-3-(4-ethoxybenzyl)phenyl]-D-glucitol; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-, (1S)-; (2S,3R,4R,5S,6R)-2-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-6-(hydroxymethyl)oxane-3,4,5-triol; 960404-48-2; Dagagflozin; (1S)-1,5-anhydro-1-C-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-D-glucitol; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-ethoxyphenyl)methyl)phenyl)-, (1S)-; (2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; BMS5121458; C-aryl glucoside, 6; PubChem22435; Tube101; Dapagliflozin (USAN/INN); 2-(3-(4-Ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,5-triol; cc-205; SCHEMBL157820; GLU006; GTPL4594; BDBM20880; DTXSID20905104; EX-A005; BCPP000265; AMY18541; AOB87300; ZINC3819138; BDBM50448923; CD0219; MFCD13182359; s1548; AKOS005145763; BCP9000583; BL-0052; CCG-229917; CS-0781; DB06292; EX-7214; PB11055; NCGC00250402-09; AC-24699; HY-10450; A25150; C22193; D08897; Q-3845; 432D268; Q409898; J-500392; BRD-K58160573-001-01-3; BRD-K58160573-001-05-4; 1-[3-(beta-D-Glucopyranosyl)-6-chlorobenzyl]-4-ethoxybenzene; (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol;BMS-512148; (2S,3R,4R,5S,6R)-2-[4-chloro-3-(4-ethoxy-benzyl)-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol
Click to Show/Hide
|
|||
| Molecular Type |
Small molecule
|
|||
| Disease | Type 2 diabetes mellitus [ICD-11: 5A11] | Approved | [1] | |
| Structure |
|
Click to Download Mol2D MOL |
||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
| Formula |
C21H25ClO6
|
|||
| PubChem CID | ||||
| Canonical SMILES |
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)C3C(C(C(C(O3)CO)O)O)O)Cl
|
|||
| InChI |
1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
|
|||
| InChIKey |
JVHXJTBJCFBINQ-ADAARDCZSA-N
|
|||
| CAS Number |
CAS 461432-26-8
|
|||
| ChEBI ID | ||||
| TTD Drug ID | ||||
| DrugBank ID | ||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
| Taxifolin | Larix gmelinii | Click to Show/Hide the Molecular Data of This NP | ||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Up-regulation | Expression | GABPA | Molecule Info | ||
| Up-regulation | Expression | JNK1 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | p105 | Molecule Info |
Pathway MAP
|
||
| Up-regulation | Expression | TLR4 | Molecule Info |
Pathway MAP
|
||
| In-vivo Model | Male rats were used to establish colistin-induced nephrotoxicity animal model in this study. | |||||
| Experimental
Result(s) |
Combined use of taxifolin and dapagliflozin may confer a therapeutic tool for attenuation of colistin-induced nephrotoxicity. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 2 (SGLT2) | Molecule Info | [3] | |
| Reactome | Hexose transport | Click to Show/Hide | ||
| 2 | Na+-dependent glucose transporters | |||
| 3 | Inositol transporters | |||
| WikiPathways | NRF2 pathway | Click to Show/Hide | ||
| 2 | Nuclear Receptors Meta-Pathway | |||
| 3 | Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | |||
